Navigation Links
Evel Knievel Lost to Pulmonary Fibrosis; Disease Claims as Many Lives as Breast Cancer Each Year
Date:11/30/2007

Urgent Need for Increased Awareness of Disease, Funding for Research

SAN JOSE, Calif., Nov. 30 /PRNewswire-USNewswire/ -- Famed stuntman Evel Knievel was known for his death defying stunts and his recovery from life threatening injuries due to those stunts. It is ironic the disease that claimed his life was one that has no treatment and no cure. Knievel was unfortunately one of 40,000 people in the U.S. who will lose their lives to idiopathic pulmonary fibrosis (IPF) this year, the same number as will die from breast cancer. Yet, most people have never heard of IPF.

IPF has no FDA approved treatment, no known cause and no cure. The disease strikes randomly, placing American adults at risk to develop it. More than 128,000 people suffer from IPF in the United States, and prevalence and incidence of the deadly disease has increased more than 150 percent in just five years.

"Our sympathies go out to the Knievel family. We know first hand the tragedy of IPF," said Mark Shreve, chief executive officer of the Coalition for Pulmonary Fibrosis (CPF). "It is devastating news to IPF patients and their families that viable treatments for IPF still do not exist. We desperately need to increase awareness of IPF and fund research that will lead to new treatments, and ultimately a cure."

For more information on IPF, visit http://www.coalitionforpf.org.

About Idiopathic Pulmonary Fibrosis (IPF)

IPF is a lung disorder characterized by a progressive scarring - known as fibrosis - and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from IPF, which is the most prevalent of a classification of lung disorders known as interstitial lung diseases (ILD's). There is currently no known cause or cure for IPF, nor is there an FDA-approved treatment. An estimated 48,000 new cases are diagnosed each year. IPF is difficult to diagnose, and an estimated two-thirds of patients die within five years of diagnosis.

About the Coalition for Pulmonary Fibrosis

The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for idiopathic pulmonary fibrosis (IPF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure pulmonary fibrosis; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of IPF issues; and works to improve awareness of IPF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 14,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with pulmonary fibrosis. For more information please visit http://www.coalitionforpf.org or call (888) 222-8541.


'/>"/>
SOURCE Coalition for Pulmonary Fibrosis
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
2. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
3. Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women
4. Resolution Recognizing Pulmonary Fibrosis Challenges Overwhelmingly Passes House
5. Deep Breeze Ltd. Launches Unique Non-Invasive, Radiation-Free Pulmonary Imaging System in the U.S.
6. Coalition for Pulmonary Fibrosis Fundraising Events Raise $280,000 for IPF
7. Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
8. A new method allows for the early diagnosis of pulmonary hypertension
9. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
10. Free Program Dec. 1 to Help Patients With Debilitating Pulmonary Disorder Alpha-1
11. Smoking may strongly increase long-term risk of eye disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology: